Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | RAD52 | P43351 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | DGKA | P23743 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12085204 | 1.00 | NAAA (0.53) | NAAAEPHX1FAAHNPSR1RAD52 | |
| SCHEMBL20012347 | 0.87 | NAAA (0.52) | NAAAEPHX1FAAHNPSR1RAD52 | |
| SCHEMBL20012348 | 0.87 | NAAA (0.52) | NAAAEPHX1FAAHNPSR1RAD52 | |
| SCHEMBL16330090 | 0.86 | ITGB3 (0.39) | NAAAEPHX1FAAHHTR2C | |
| SCHEMBL17586072 | 0.86 | NAAA (0.51) | NAAAEPHX1FAAHNPSR1RAD52 | |
| SCHEMBL19508718 | 0.86 | NAAA (0.56) | NAAAEPHX1FAAHNPSR1RAD52 | |
| SCHEMBL19508498 | 0.86 | NAAA (0.51) | NAAAEPHX1FAAHNPSR1RAD52 | |
| SCHEMBL28821757 | 0.84 | NAAA (0.50) | NAAAEPHX1FAAHNPSR1RAD52 | |
| SCHEMBL8349662 | 0.84 | NAAA (0.50) | NAAAEPHX1FAAHNPSR1RAD52 | |
| SCHEMBL12085206 | 0.84 | NAAA (0.50) | NAAAEPHX1FAAHNPSR1RAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170304403-A1 | METHOD FOR INHIBITING INFLAMMATION and PRO-INFLAMMATORY CYTOKINE/CHEMOKINE EXPRESSION USING A GHRELIN ANALOGUE | IPSEN PHARMA S.A.S. (FR) | 2017-10-26 | — | — | US | disclosed |
| US-20150111823-A1 | METHOD FOR INHIBITING INFLAMMATION and PRO-INFLAMMATORY CYTOKINE/CHEMOKINE EXPRESSION USING A GHRELIN ANALOGUE | IPSEN PHARMA S.A.S. (FR) | 2015-04-23 | — | — | US | disclosed |
| US-8871706-B2 | Method for inhibiting inflammation and pre-inflammatory cytokine/chemokine expression using a ghrelin analogue | IPSEN PHARMA S.A.S. (FR) | 2014-10-28 | — | — | US | disclosed |
| US-20110160133-A1 | METHOD FOR INHIBITING INFLAMMATION AND PRE-INFLAMMATORY CYTOKINE/CHEMOKINE EXPRESSION USING A GHRELIN ANALOGUE | IPSEN PHARMA S.A.S. (FR) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304403-A1 | METHOD FOR INHIBITING INFLAMMATION and PRO-INFLAMMATORY CYTOKINE/CHEMOKINE EXPRESSION USING A GHRELIN ANALOGUE | PROKR1, CCL2, PROKR2 | NAAA 2491/4885EPHX1 1534/4885FAAH 785/4885 |
| US-20150111823-A1 | METHOD FOR INHIBITING INFLAMMATION and PRO-INFLAMMATORY CYTOKINE/CHEMOKINE EXPRESSION USING A GHRELIN ANALOGUE | PROKR1, CCL2, PROKR2 | NAAA 2491/4885EPHX1 1534/4885FAAH 785/4885 |
| US-20110160133-A1 | METHOD FOR INHIBITING INFLAMMATION AND PRE-INFLAMMATORY CYTOKINE/CHEMOKINE EXPRESSION USING A GHRELIN ANALOGUE | PROKR1, PROKR2, CCL2 | NAAA 2600/4885EPHX1 1546/4885FAAH 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.